Design, synthesis and biological evaluation of 4-(1- (4(sulphanilamide) phenyl)-3-(methyl)-1H-pyrazol-5-yl)dine urea and N-acyl derivatives as a soluble epoxide hydrolase inhibitors

Medicinal Chemistry Research

Volumn 23, Issue 5, 2014, Pages 2178-2197

  Nimbarte, Vijaykumar D ^a   Murtuza, Hadianawala ^a   Phaniraj, Sahishna ^a   Shrivastava, Shweta ^a   Naidu, V G M ^a   Satheesh Kumar, N ^a   Atcha, Krishnam Raju ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

(1,5) Diarylpyrazole derivatives; AUDA; Hypertension; N Acyl; sEH inhibition; Urea

Indexed keywords

(4 CHLOROPHENYL)[4 [3 METHYL 1 [4(METHYLSULPHONYL) PHENYL] 1H PYRAZOL 5 YL]PIPERIDIN 1 YL]METHANONE; (4 METHOXYPHENYL) [4 [3 METHYL 1 [(METHYLSULPHONYL) PHENYL] 1H PYRAZOL 5 YL]PIPERIDIN 1 YL]METHANONE; 1 [4 [3 METHYL 1 [4 (METHYLSULPHONYL)PHENYL] 1H PYRAZOL 5 YL]PIPERIDIN 1 YL]PROPAN 1 ONE; 4 [3 METHYL 1 (4 SULPHAMOYLPHENYL) 1H PYRAZOL 5 YL] N PROPYLPIPERIDINE 1 CARBOXAMIDE; 4 [3 METHYL 1 (4 SULPHAMOYLPHENYL)1H PYRAZOL 5 YL] N 4 TOLYLPIPERIDINE 1 CARBOXAMIDE; 4 [3 METHYL 1 [4 (METHYLSULPHONYL)PHENYL] 1H PYRAZOL 5 YL] N PHENYLPIPERIDINE 1 CARBOXAMIDE; 4 [3 METHYL 1 [4 (METHYLSULPHONYL)PHENYL] 1H PYRAZOL 5 YL] N PROPYLPIPERIDINE 1 CARBOXAMIDE; 4 [3 METHYL 5 (1 PROPIONYLPIPERIDIN 4 YL) 1H PYRAZOL 1 YL]BENZENESULPHONAMIDE; 4 [3 METHYL 5 [1 (4 METHYLBENZOYL)PIPERIDIN 4 YL] 1H PYRAZOL 1 YL]BENZENESULPHOMIDE; 4 [3 METHYL 5 [1 (4 NITROBENZOYL)PIPERIDIN 4 YL] 1H PYRAZOL 1 YL]BENZENESULPHONAMIDE; 4 [5 (1 BENZOYLPIPERIDIN 4 YL) 3 METHYL 1H PYRAZOL 1 YL]BENZENESULPHONAMIDE; 4 [5 [1 (4 CHLOROBENZOYL)PIPERIDIN 4 YL] 3 METHYL 1H PYRAZOL 1 YL]BENZENE SULPHONAMIDE; 4 [5 [1 (4 METHOXYBENZOYL)PIPERIDIN 4 YL] 3 METHYL 1H PYRAZOL 1 YL]BENZENESULPHONAMIDE; EPOXIDE HYDROLASE INHIBITOR; HYDROLASE INHIBITOR; N (4 CHLOROPHENYL) 4 [3 METHYL 1 (4 SULPHAMOYLPHENYL) 1H PYRAZOL 5 YL]PIPERIDINE 1 CARBOXAMIDE; N BENZYL 4 [3 METHYL 1 (4 SULPHAMOYLPHENYL) 1H PYRAZOL 5 YL]PIPERIDINE 1 CARBOXAMIDE; N BENZYL 4 [3 METHYL 1 (4 SULPHAMOYLPHENYL)1H PYRAZOL 5 YL]PIPERIDINE 1 CARBOXAMIDE; N BUTYL 4 [3 METHYL 1 (4 SULPHAMOYLPHENYL)1H PYRAZOL 5 YL]PIPERIDINE 1 CARBOXAMIDE; N BUTYL 4 [3 METHYL 1 [4 (METHYLSULPHONYL)PHENYL] 1H PYRAZOL 5 YL]PIPERIDINE 1 CARBOXAMIDE; N CYCLOHEXYL 4 [3 METHYL 1 (4 SULPHAMOYLPHENYL)1H PYRAZOL 5 YL]PIPERIDINE 1 CARBOXAMIDE; N CYCLOHEXYL 4 [3 METHYL 1 [4 (METHYLSULPHONYL)PHENYL] 1H PYRAZOL 5 YL]PIPERIDINE 1 CARBOXAMIDE; N ETHYL 4 [3 METHYL 1 (4 SULPHAMOYLPHENYL) 1H PYRAZOL 5 YL]PIPERIDINE 1 CARBOXAMIDE; N ETHYL 4 [3 METHYL 1 [4 (METHYLSULPHONYL)PHENYL] 1H PYRAZOL 5 YL]PIPERIDINE 1 CARBOXAMIDE; N ISOPROPYL 4 [3 METHYL 1 (4 SULPHAMOYLPHENYL)1H PYRAZOL 5 YL]PIPERIDINE 1 CARBOXAMIDE; N ISOPROPYL 4 [3 METHYL 1 [4 (METHYLSULPHONYL)PHENYL] 1H PYRAZOL 5 YL]PIPERIDINE 1 CARBOXAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; [4 [3 METHYL 1 [4 (METHYLSULPHONYL)PHENYL] 1H PYRAZOL 5YL]PIPERIDIN 1 YL] (PHENYL)METHANONE; [4 [3 METHYL 1 [4 (METHYLSULPHONYL)PHENYL] 1H PYRAZOL 5YL]PIPERIDIN 1 YL](4 NITROPHENYL)METHANONE; [4 [3 METHYL 1 [4 (METHYLSULPHONYL)PHENYL]1H PYRAZOL 5YL]PIPERIDIN 1 YL](4 TOLY)METHANONE;

ARTICLE; BINDING AFFINITY; CHEMICAL BOND; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; GEOMETRY; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; IC 50; IN VITRO STUDY; MOLECULAR DOCKING; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

EID: 84898826711     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-013-0817-8     Document Type: Article

References (37)

1. Anton R, Camacho M, Puig L, Vila L (2002) Hepoxilin B3 and its enzymatically formed derivative trioxilin B3 are incorporated into phospholipids in psoriatic lesions. J Invest Dermatol 118:139-146 (Pubitemid 34107435)
2. Arand M, Wagner H, Oesch F (1996) Asp333, Asp495, and His523form the catalytic triad of rat soluble epoxide hydrolase. J Biol Chem 271:4223-4229
3. Atcha KR, Srinivas K, Phaniraj SM, Nimbarte VD, Murtuza SH (2012) Design and in silico studies of 4-(1-(4-sulfonamide/methylsulfonyl)phenyl)-3- (trifluoromethyl/methyl)-1H-pyrazol-5-yl)dine urea and amide derivatives as novel potent dual acting agents: selective COX-2 and soluble epoxide hydrolase (sEH) inhibitors. Int Conf Biol Active Mol 9:209-211
4. Campbell WB, Gebremedhin D, Pratt PF, Harder DR (1996) Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78:415-423 (Pubitemid 26072547)
5. Chan DS, Lee HM, Yang F, Che CM, Wong CCL, Abagyan R, Leung CH, Ma DL (2010) Structure-based discovery of natural-product-like TNF-α inhibitors. Angew Chem Int Ed 49:2860-2864
6. Dailey LA, Imming P (1999) 12-Lipoxygenase: classification, possible therapeutic benefits from inhibition and inhibitors. Curr Med Chem 6:389-398 (Pubitemid 29230821)
7. Eldrup AB, Soleymanzadeh F, Farrow NA, Kukulka A, De Lombaert S (2010) Optimization of piperidyl-ureas as inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett 20:571-575
8. Falck JR, Reddy LM, Reddy YK (2003) 11,12-Epoxyeicosatrienoic acid (11,12-EET): structural determinants for inhibition of TNF-alpha induced VCAM-1 expression. Bioorg Med Chem Lett 13:4011-4014 (Pubitemid 37338437)
9. Fang X, Kaduce TL, Weintraub N (2001) Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells: implication for the vascular effects of soluble epoxide hydrolase inhibition. J Biol Chem 276:14867-14874
10. Fitzpatrick FA, Ennis MD, Baze ME (1986) Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry. J Biol Chem 261:15334-15338 (Pubitemid 17218115)
11. Fretland AJ, Omiecinski CJ (2000) Epoxide hydrolases: biochemistry and molecular biology. Chem Biol Interact 129:41-59 (Pubitemid 32061053)
12. Friesen RW, Mancini JA (2008) Microsomal prostaglandin E synthase-1 (mPGES-1): a novel antiinflammatory therapeutic target. J Med Chem 51:4059-4067 (Pubitemid 352032432)
13. Huang SX, Li HY, Liu JY, Morisseau C, Hammock BD (2010) Incorporation of piperazino functionality into 1,3-disubstituted urea as the tertiary pharmacophore affording potent inhibitors of soluble epoxide hydrolase with improved pharmacokinetic properties. J Med Chem 53:8376-8386
14. Hwang SH, Morisseau C, Do Z, Hammock BD (2006) Solid-phase combinatorial approach for the optimization of soluble epoxidehydrolase inhibitors. Bioorg Med Chem Lett 16:5773-5775
15. Hwang SH, Tsai HJ, Liu JY, Morisseau C, Hammock BD (2007) Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem 50:3540-3825
16. Hwang SH, Wagner KM, Morisseau C, Liu JY, Dong H, Aaron T, Wecksler AT, Hammock BD (2011) Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase. J Med Chem 54:3037-3050
17. Iber H, Chen Q, Cheng PY (2000) Suppression of CYP2C11 gene transcription by interleukin-1 mediated by NF-kappaB binding at the transcription start site. Arch Biochem Biophys 377:187-194 (Pubitemid 30257304)
18. Kessler P, Popp R, Busse R (1999) Proinflammatory mediators chronically down regulate the formation of the endothelium-derived hyperpolarizing factor in arteries via a nitric oxide/cyclic GMP-dependent mechanism. Circulation 99:1878-1884 (Pubitemid 29181418)
19. Kim IH, Heirtzler FR, Morisseau C, Nishi K, Tsai HJ, Hammock BD (2005) Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem 48:3621-3629 (Pubitemid 40664110)
20. Morisseau C, Hammock BD (2005) Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol 45:311-333 (Pubitemid 40261808)
21. Morisseau C, Newman JW, Dowdy DL, Goodrow MH, Hammock BD (2001) Inhibition of microsomal epoxide hydrolases by ureas, amides and amines. Chem Res Toxicol 14:409-415 (Pubitemid 32367474)
22. Newman JW, Morisseau C, Hammock BD (2005) Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog Lipid Res 44:1-51 (Pubitemid 40313218)
23. Node K, Huo Y, Ruan X (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285:1276-1279 (Pubitemid 29398616)
24. Node K, Ruan XL, Dai J (2001) Activation of G as mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoicacids. J Biol Chem 276:15983-15989
25. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Rogier DJ, Lee LF, Yu SS, Anderson GD, Koboldt CM (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3(trifluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J Med Chem 40:13-1347
26. Rose TE, Morisseau C, Liu JY, Inceoglu B, Jones PD, Sanborn JR, Hammock BD (2010) 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain. J Med Chem 2010(53):7067-7075
27. Samuelsson B, Morgenstern R, Jakobsson PJ (2007) Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 59:207-224 (Pubitemid 47481434)
28. Shen HC, Ding FX, Wang S, Deng Q, Zhang X, Chen Y, Zhou G, Xu S, Chen HS, Tong T, Tong V, Mitra K, Kumar S (2009a) Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement. J Med Chem 52:5009-5012
29. Shen HC, Ding FX, Deng Q, Xu S, Chen HS, Tong X, Tong V, Zhang X, Chen Y, Zhou G, Pai LY, Alonso GM, Zhang B, Roy S, Tata JR, Berger JP, Colletti SL (2009b) Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett 19:5314-5320
30. Smith AS, Oslob JD, Flanagan WM, Braisted AC, Whitty A, Cancilla MT, Wang J, Lugovskoy AA, Yoburn JC, Fung AD, Farrington G, Eldredge JK, Day ES, Cruz LA, Cachero TG, Miller SK, Friedman JE, Choong IC, Cunningham BC (2005) Small-molecule inhibition of TNF-alpha. Science 310:1022-1025
31. Sonda S, Kawahara T, Murozono T, Sato N, Asano K, Haga K (2003) Design and synthesis of orally active benzamide derivatives as potent serotonin 4 receptor agonist. Bioorg Med Chem 11:4225-4234 (Pubitemid 37013573)
32. Spector AA, Fang X, Snyder GD, Weintraub NL (2004) Epoxyeicosatrienoic acids (EETs) metabolism and biochemical function. Prog Lipid Res 43:55-90 (Pubitemid 37433867)
33. Taylor PC (2007) The future of TNF-α antagonism. Future Rheumatol 2:233-236
34. Wallace JL, Ignarro LJ, Fiorucci S (2002) Potential cardio protective actions of NO-releasing aspirin. Nat Rev Drug Discov 1:375-382 (Pubitemid 37361467)
35. Wells JA, McClendon CL (2007) Reaching for high-hanging fruit in drug discovery at protein interfaces. Nature 450:1001-1009 (Pubitemid 350273630)
36. Xiang F (2006) Recent Pat Cardiovasc Drug Discov 1:1-7
37. Zalewski A, Nelson JJ, Heg JJ, Macphee C (2006) Lp-PLA22: a new kid on the block. Clin Chem 52:1645-1649